Yuhan USA

???? ?? ?? ?? ????? ????? ????? ???. ????, ?? ?? ?? ??? ??? ??? ??? ??? ????. https://lnkd.in/eDYFfyPp #hiring

RYBREVANT? plus LAZCLUZE? shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib? J&J? EGFRxMET ???? ‘????? (??? ?????)’? ????? ??? J&J? ??????? 3?? EGFR TKI ‘????? (??? ?????)’? ???? ?? ??? OS? ?????, ????? ????? ????? ??. Johnson & Johnson has announced that its chemotherapy-free combination of Rybrevant? (amivantamab-vmjw) and LAZCLUZE? (lazertinib) has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC).? This combination therapy is the first to show a survival benefit over the current standard of care in the first-line treatment of EGFR-mutated lung cancer. The improvement in median OS is expected to exceed one year.? These findings are based on the Phase 3 MARIPOSA study, which previously demonstrated that the Rybrevant and lazertinib combination significantly reduced the risk of disease progression or death by 30% compared to osimertinib.? In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE? (marketed as LACLAZA in Korea). LAZCLUZE? is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR. https://lnkd.in/euSWT5V2 #Yuhan, #YuhanUSA, #JandJ, #JohnsonandJohnson, #JanssenBiotech, #Lazcluse, #Lazertinib, #Rybrevant ,#amivantamab, #Laclaza, #NSCLC

European Commission approves RYBREVANT? in combination with LAZCLUZE? for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer? ???? ?????? EGFR ?? ??? ?????? ??? 1? ???? J&J? RYBREVANT?(amivantamab)? ????? ??? J&J? ???????LAZCLUZE?(lazertinib)?? ?? ??? ???. The European Commission has approved the combination of RYBREVANT? (amivantamab) and LAZCLUZE? (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or L858R substitution mutations.? This approval is based on results from the Phase 3 MARIPOSA study, which demonstrated that the amivantamab and lazertinib combination significantly reduced the risk of disease progression or death by 30% compared to osimertinib monotherapy.? The study also showed a nine-month improvement in median duration of response for patients receiving the combination therapy. This chemotherapy-free regimen offers a new standard of care for patients with EGFR-mutated advanced NSCLC. In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE? (marketed as LACLAZA in Korea). LAZCLUZE? is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR. https://lnkd.in/eVHpGZGQ #Yuhan, #YuhanUSA, #JandJ, #JohnsonandJohnson, #JanssenBiotech, #Lazcluse, #Lazertinib, #Rybrevant, #amivantamab, #Laclaza, #NSCLC

RYBREVANT??plus LAZCLUZE? by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE? is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.?? ? Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT??(amivantamab-vmjw) plus LAZCLUZE? (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.? Yuhan Corporation in-licensed lazertinib?in 2015 from Genosco Inc. In 2018, Jassen Biotech Inc., based on results from the phase 1/2 clinical trial conducted in Korea,?entered a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE? (lazertinib, marketed as LACLAZA in Korea). ? RYBREVANT??plus LAZCLUZE? becomes the first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus osimertinib approved for the first-line treatment of patients with EGFR-mutated NSCLC. ? RYBREVANT??is an EGFR- and MET*-directed bispecific antibody that engages the immune system, and LAZCLUZE? is a highly selective, brain-penetrant, third-generation oral EGFR TKI. RYBREVANT??plus LAZCLUZE??is the only multitargeted regimen targeting both the common EGFR mutations directly.

We’re #hiring. Know anyone who might be interested? Please feel free to share this information with others who may be interested. https://lnkd.in/e8r_UnE3

Yuhan USA team attended NEBS 2024 32nd?Annual Conference on May 18th?at the Harvad Medical School. Yuhan is a proud sponsor of NEBS and It’s always great to connect with such a talented group of scientists. Special?congratulations?to Dr. Won-Seok Lee for receiving NEBS-Yuhan award! His work on?“Cells with intranuclear Huntingtin aggregates have long (>150) somatic CAG-repeat expansions and associated transcriptional pathology”?was indeed impressive. We look forward to reconnecting at the next event! ? New England Bioscience Society, Inc. (NEBS) is a non-profit organization of Korean scientists in the fields of life sciences and biotechnology in New England and Pennsylvania areas. Since its foundation in 1984, NEBS has been dedicated to promoting scientific and social communications and networking among the members.

Yuhan USA will be participating in 2024 BIO International Convention on June 3-6. Attending BIO 2024??Let’s connect!?Send?us?a meeting request in the BIO partnering system!?#BIO2024 https://lnkd.in/eByHFz94